


UBS Italian Equity Capital Markets

Credentials as of March 2023



Leading player in Italian ECM

1

UBS' capabilities combine a **global footprint** with extensive **on-the-ground presence in Italy** and **knowledge of the Italian market**

















2

With **41** transactions and more than **€58bn in equity raised for Italian corporates** since 2010, UBS is a **leading bank in Italian equity capital markets**

3

A waterfront sales coverage combined with the largest WM platform in the world result in the ability to **deliver unique and differentiated demand for our clients**

UBS transactions in the Italian stock exchange and transactions for Italian corporates on foreign stock exchanges

 <p>2023, €73m ABB UBS acted as Joint Global Coordinator and Joint Bookrunner</p>	 <p>2021, €350m IPO UBS acted as Joint Global Coordinator</p>	 <p>2021, \$250m UBS acted as Co-lead PIPE Placement Agent</p>	 <p>2021, €212m ABB UBS acted as Sole Bookrunner</p>	 <p>2021, \$693m IPO UBS acted as Joint Bookrunner</p>
 <p>2021, €220m SPAC IPO UBS acted as Joint Global Coordinator</p>	 <p>2020, €800m ABB UBS acted as Joint Bookrunner</p>	 <p>July 2019, €1,099m ABB; May 2019, €1,014m ABB UBS acted as Joint Global Coordinator</p>	 <p>2019, €2,056m IPO UBS acted as Joint Bookrunner</p>	 <p>2017, €188m ABB UBS acted as Sole Bookrunner</p>
 <p>2017, €13,000m UBS acted as Structuring Advisor and Joint Global Coordinator</p>	 <p>2017, €175m ABB UBS acted as Joint Bookrunner</p>	 <p>2017, €500m Convertible Bond UBS acted as Joint Global Coordinator and Joint Bookrunner</p>	 <p>Oct 2016, €552m ABB; Jul 2016, €328m ABB UBS acted as Joint Global Coordinator</p>	 <p>2015, €3,112m IPO UBS acted as Joint Bookrunner</p>
 <p>2015, \$982m IPO UBS acted as Sole Global Coordinator and Lead Left Bookrunner</p>	 <p>2015, €875m IPO UBS acted as Joint Bookrunner</p>	 <p>2015, €3,000m Rights Issue UBS acted as Sole Global Coordinator and Joint Bookrunner</p>	 <p>2015, €100m ABB UBS acted as Sole Bookrunner</p>	 <p>2014, €2,320 Convertible Bond and €891m Follow-On UBS acted as Active Bookrunner</p>
 <p>2014, €5,000m Rights Issue UBS acted as Global Coordinator and Joint Bookrunner</p>	 <p>2014, €774m IPO UBS acted as Joint Global Coordinator</p>	 <p>2014, €215m ABB UBS acted as Sole Bookrunner</p>	 <p>2014, €1,498m Rights Issue UBS acted as Joint Global Coordinator</p>	 <p>2014, €759m IPO UBS acted as Joint Bookrunner</p>

DISCLAIMER

By accepting this document, the recipient agrees to be bound by the following obligations and limitations.

Provenance and purpose. This presentation has been issued by UBS AG London Branch (“**UBS**”) for the exclusive use of the party to whom UBS delivers this presentation (the “**Recipient**”) using information provided by the Recipient and other publicly available information.

No independent verification. The information in this presentation has been obtained from the Recipient and other publicly available sources and has not been independently verified by UBS Group AG and/or its subsidiaries, branches or affiliates (together, the “**UBS Group**”) or any of its directors, officers, employees, agents, representatives or advisers or any other person. The UBS Group has relied on the Recipient to (i) provide the UBS Group with all information relevant for the purposes of the presentation, and (ii) ensure that such information is and remains complete, true and accurate in all material respects and is not misleading, whether by omission or otherwise.

No representation or warranty. No representation, warranty or undertaking, express or implied, is or will be given by the UBS Group or its directors, officers, employees, agents, representatives and/or advisers (i) as to or in relation to the accuracy, completeness, reliability or sufficiency of the information contained in this presentation (including any pricing quotation), (ii) as to the reasonableness of any assumption contained in this presentation or (iii) as to any indicative performance or indicative future return or fitness for any particular purpose of any analysis or calculation methodology.

No Liability. By accepting receipt of this presentation, the Recipient acknowledges and agrees that to the maximum extent permitted by applicable law, the UBS Group and its directors, officers, employees and agents expressly disclaim any liability which may arise from this presentation, or any other written or oral information provided in connection with this presentation, and any errors contained therein and/or omissions therefrom or from relying on or any use of the contents of this presentation or otherwise in connection with this presentation, including for any loss or damage arising out of use or reliance by the Recipient or any other person upon (or the use of or inability to use) any indicative pricing quotation or any scenario analysis or any error of the UBS Group in connection with the compilation, methodology, interpretation, communication, publication or delivery of any analysis.

Indicative price quotations. Any price quotations shown in this presentation are indicative only and show preliminary estimates of the price at which the UBS Group would purchase (bid) or sell (offer) the relevant instruments as at the date and time of publication (such price quotations are commonly referred to as “**indicative price quotations**”). Any such indicative price quotations are subject to change without notice at the sole discretion of the UBS Group and should not be used for valuation or any other purposes.

Preparation of indicative price quotations. Any indicative price quotations are provided in good faith using the UBS Group’s standard methodology for quotations of this kind. That methodology relies on proprietary models, empirical data and assumptions that we believe to be accurate and reasonable. However, the UBS Group makes no representation as to the accuracy, completeness or appropriateness of such methodology. In preparing any indicative price quotations, the UBS Group may take into account such factors as it deems appropriate (including, but not limited to, profit, credit risk, convertibility risk factors, hedging and transaction costs, market liquidity and bid-ask spreads). Any indicative price quotations have been prepared as of a particular date and time and will therefore not reflect subsequent changes in market values or prices or in any other factors relevant to their determination.

Nature of indicative price quotations. Any indicative price quotations (i) should not be taken to suggest that any transactions have or will take place at these prices and (ii) do not constitute firm bids or offers or any other solicitation to conclude a transaction at the level stated. The Recipient should note that any request for firm, currently tradable bid or offer prices may result in different prices to reflect such factors as hedging and transaction costs, credit considerations, and market liquidity. Any transaction between the Recipient and the UBS Group will be subject to agreement on the actual price and such additional terms as are agreed. Prior to entering into any transaction with the UBS Group, the Recipient should consult with its own legal, regulatory, tax, business, investment, financial, accounting and any other advisers to the extent that the Recipient deems it necessary, and the Recipient should make its own investment, hedging and trading decisions (including decisions regarding the suitability of the transaction) based upon its own judgment and advice from such advisers as the Recipient deems necessary and not upon any view expressed by the UBS Group.

Scenario analysis. Any scenario analysis included is provided to the Recipient by UBS for informational purposes only and should not be used in substitution for the exercise of independent judgment. Any assumptions and parameters used are not the only ones that might reasonably have been selected and therefore no guarantee is given as to the accuracy, completeness or reasonableness of any such quotations, disclosure or analyses. Any analysis may be based in part on information and market data which may be subject to change. The UBS Group shall not be under any obligation to update any analysis.

Forecasts. The valuations, projections, estimates, forecasts, targets, prospects, returns and/or opinions (including, without limitation, projections of revenue, expense, net income and stock performance) contained herein involve elements of subjective judgment and analysis. Any opinions, indicative price quotations, information and/or analysis expressed in this material are subject to change without notice. Opinions may differ or be contrary to opinions expressed by other business areas or groups of the UBS Group as a result of using different assumptions and criteria. This presentation may contain forward-looking statements. UBS gives no undertaking and is under no obligation to update these forward-looking statements for events or circumstances that occur subsequent to the date of this presentation. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future or that any of the estimates or projections contained herein will be achieved.

No duty to update. This presentation speaks as at the date hereof (unless an earlier date is otherwise indicated in the presentation) and in furnishing this presentation, no obligation is undertaken and nor is any representation or undertaking given by any person to provide the recipient with additional information or to update, revise or reaffirm the information in this presentation or to correct any inaccuracies therein which may become apparent.

Information only. This presentation has been prepared solely for informational or educational purposes and does not suggest taking or refraining from any action. It does not constitute or contain an offer, invitation or a solicitation to buy or sell any securities or related financial instruments or any of the assets, business or undertakings described herein.

No advice given. The Recipient should not construe the contents of this presentation as legal, tax, accounting or investment advice or a personal recommendation. The Recipient should consult its own counsel, tax and financial advisers as to legal and related matters concerning any transaction described herein. This presentation does not purport to be all-inclusive or to contain all of the information that the Recipient may require or request upon due diligence if it wishes to proceed further. By providing this presentation, UBS does not have the responsibility or authority to provide, nor has provided, investment advice to the Recipient in a fiduciary capacity with regard to the matters contained herein. No investment, divestment or other financial decisions or actions should be based solely on the information in this presentation. This presentation should not be viewed as an investment recommendation because it is provided as part of the general marketing and advertising activities of UBS.

No distribution. This presentation has been prepared on a confidential basis solely for the use and benefit of the Recipient. Distribution of this presentation to any person other than the Recipient and those persons retained to advise the Recipient, who agree to maintain the confidentiality of this material and be bound by the limitations outlined herein, is unauthorized. This material must not be copied, reproduced, published, distributed, passed on or disclosed (in whole or in part) to any other person or used for any other purpose at any time without the prior written consent of UBS. UBS shall be free to disclose all or part of the presentation as required by any law, regulation or order of a court or pursuant to an order, requirement or request of a regulatory body having authority over UBS, or pursuant to governmental action, or necessary in the view of UBS to seek to establish any defence in any legal or regulatory proceeding or investigation or otherwise to comply with its own regulatory obligations.

Role of UBS. By accepting this presentation, the Recipient acknowledges and agrees that UBS is acting, and will at all times act, as an independent contractor on an arm’s length basis and is not acting, and will not act, in any other capacity, including in a fiduciary capacity, with respect to the Recipient. UBS may only be regarded by you as acting on your behalf as financial adviser or otherwise following the execution of appropriate documentation between us on mutually satisfactory terms.

Conflicts of Interest. The UBS Group may from time to time, as principal or agent, be involved in a wide range of commercial banking and investment banking activities globally (including investment advisory, asset management, research, securities issuance, trading (customer and proprietary) and brokerage), have long or short positions in, or may trade or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which this presentation relates. The UBS Group’s banking, trading and/or hedging activities may have an impact on the price of the underlying asset and may give rise to conflicting interests or duties. The UBS Group may provide services to any member of the same group as the Recipient or any other entity or person (a “Third Party”), engage in any transaction (on its own account or otherwise) with respect to the Recipient or a Third Party, or act in relation to any matter for itself or any Third Party, notwithstanding that such services, transactions or actions may be adverse to the Recipient or any member of its group, and the UBS Group may retain for its own benefit any related remuneration or profit.

Research. This presentation may contain references to research produced by the UBS Group. Research is produced for the benefit of the firm’s investing clients. The primary objectives of each analyst in the research department are: to analyse the companies, industries and countries they cover and forecast their financial and economic performance; as a result, to form opinions on the value and future behavior of securities issued by the companies they cover; and to convey that information to the UBS Group’s investing clients. Each issuer is covered by the Research Department at its sole discretion. The Research Department produces research independently of other business areas of the UBS Group and UBS AG business groups.

UBS AG London Branch is authorised and regulated by the Financial Market Supervisory Authority in Switzerland. It is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority in the United Kingdom.

© UBS 2023. All rights reserved. UBS specifically prohibits the redistribution of this material and accepts no liability whatsoever for the actions of third parties in this respect.